Physician profile
Abiola J Grant
NPI 1508405044
$6,168.24
in general payments reported to CMS, 2019-2025
31 companies · $2,831 in 2025
The $2,831 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $212 · 2023: $1,243 · 2024: $1,883 · 2025: $2,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,888 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,887.53 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,433.22 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,245.32 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $958.14 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $738.45 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $249.90 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.14 | 2023-2025 | Xifaxan, Trulance |
| Amgen INC. | $185.72 | 2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $139.51 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $118.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $108.35 | 2023-2025 | Gardasil 9, Verquvo, Gardasil |
| Lilly USA, LLC | $96.81 | 2023-2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $95.80 | 2024-2025 | Inspire |
| Axsome Therapeutics, INC. | $75.44 | 2025 | Auvelity, Sunosi |
| Ardelyx, INC. | $55.12 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $50.30 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.50 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $36.78 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.63 | 2022-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $29.17 | 2023-2024 | Quviviq |
| Ironwood Pharmaceuticals, INC | $29.15 | 2023-2024 | Linzess |
| Ani Pharmaceuticals, INC. | $28.24 | 2025 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $23.66 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $22.30 | 2025 | Gvoke Hypopen |
| Viatris Specialty LLC | $21.67 | 2025 | Yupelri |
| Lundbeck LLC | $20.85 | 2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $19.16 | 2023 | Xtampza |
| Takeda Pharmaceuticals U.S.A., INC. | $18.06 | 2022 | |
| Indivior INC. | $16.98 | 2025 | Sublocade |
| Jazz Pharmaceuticals INC. | $15.54 | 2023 | |
| Neurocrine Biosciences, INC. | $15.47 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abiola Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.